SOUTH EASTON, MA / ACCESSWIRE / October 17, 2016 / Pressure BioSciences, Inc. (OTCQB: PBIO) ("PBI" or the "Company") today announced that Mr. Richard T. Schumacher, President and CEO, will present a corporate overview and business update at the SeeThruEquity ("STE") Fall Microcap Investment Conference in New York City. Mr. Schumacher's presentation at STE is scheduled for Monday, October 17 at 11:30am at the Convene Grand Central (101 Park Avenue Avenue).

Mr. Schumacher's presentation will be webcast and may be viewed live at the following link (http://wsw.com/webcast/seethru17/pbio) and up to 90 days thereafter on the Company's website (www.pressurebiosciences.com). Each company will be provided with a 30-minute time slot to present to an audience of investors and industry professionals and company management will also be available for one-on-one meetings with institutional investors.

Conference registration: complimentary for qualified investors and equity research analysts.

In order to register as an attendee of the conference, please click HERE.

About SeeThruEquity

Since the company's founding in 2011, SeeThruEquity (STE) has been committed to its core mission: providing impactful, high quality research on uncovered/undercovered microcap stocks and hosting investor conferences throughout the year. STE has grown its research universe to over 190 names.

STE conferences are the ultimate event for publicly traded companies with less than $1 billion in market capitalization because it augments the conference experience with the firm's research, which is part of Wall Street consensus and available across industry leading platforms including Thomson First Call, FactSet, S&P CapitalIQ, Yahoo! Finance and Bloomberg to name a select few. STE has hosted 20 investor conferences which have showcased over 350 companies, attracted over 4500 attendees and have included over 1,700 1-on-1 meetings. For more information please visit www.steconference.com.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary development and sales efforts are in the biomarker discovery, drug discovery and design, and forensics areas. Customers also use our products in other areas, such as bio-therapeutics characterization, soil & plant biology, vaccine development, and counter-bioterror applications.

For more information about PBI and this press release, please click on the following website link: http://www.pressurebiosciences.com.

Please Visit us on Facebook, LinkedIn, and Twitter

SOURCE: Pressure BioSciences, Inc.